Anti-psychotic
medications, often known as tranquillizers or neuroleptics, are a class of
medication commonly used to treat schizophrenia and bipolar illness. They're
used to treat psychosis, which includes hallucinations, delusions, and paranoid
thoughts, among other things. Antipsychotic medications are successful in
treating psychosis in a short period of time. These medications inhibit the
action of dopamine, which is directly connected to psychotic symptoms, by
blocking dopamine receptors in the brain's dopaminergic pathways. Antipsychotic
use has increased as the prevalence of mental disorder has increased. According
to the National Alliance of Mental Illness, one in every five adults suffers
from mental illness, accounting for 18.5 percent of the overall population.
Long-term use of these medications, on the other hand, may cause adverse
effects such metabolic syndrome and involuntary movement disorder, leading to
an increase in mortality in the older population with dementia.
Increase in prevalence of mental
disorders to fuel the growth of anti-psychotic drugs market
Schizophrenia
is the leading cause of psychosis worldwide, and patients with the illness are
more likely to develop physical and mental illnesses. In 2016, approximately 21
million people worldwide were diagnosed with schizophrenia, according to the
World Health Organization (WHO). According to the WHO, one out of every two
patients with schizophrenia does not receive adequate treatment. This is an
opportunity for industry participants in the worldwide anti-psychotic
medicines market to find cost-effective treatments for this disease.
Furthermore, according to the National Alliance of Medical Illness,
approximately 1.1 percent of adults in the United States suffer from
schizophrenia, while 2.6 percent suffer from bipolar disorder. In a given year,
one in every five individuals in the United States, or 43.8 million people, or
18.5 percent of the overall population, suffers from some form of mental
illness. The market for antipsychotic medications is growing due to the high
frequency and increasing incidence of neurological illnesses.
Increase in drug abuse and increasing
incidence of drug addiction inadvertently fueling growth of global
anti-psychotic drugs market
The rising
frequency of Schizophrenia and psychotic diseases is a primary driver of the
worldwide anti-psychotic medications industry. Several other causes, such as
rising drug abuse rates, overprescription of psychotic medicines, and
antipsychotic drug addiction, also contribute to market expansion. According to
the National Survey on Substance Use and Health (NSDUH), in 2012, 13.2 percent
of the US population (almost 4 million people) used an illegal drug or misused
a psychotherapeutic medication. However, the recent patent expiration of key
brands has had a detrimental impact on market growth. Furthermore,
anti-psychotics' side effects, which include tardive dyskinesia, sleeplessness,
and a variety of other problems, are limiting the worldwide anti-psychotic
medications market's growth.
Comments
Post a Comment